ClinicalTrials.gg
CompletedNCT03581370CEFTOREAUpdated Nov 9, 2026

Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients With Ventilator Associated-pneumonia

A Phase 3 interventional study of 1 hour infusion and 4 hours infusion in Ventilator-associated Pneumonia, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Toulouse · Phase 3, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Pneumonia, Ventilator-Associated with a site in France — 20 open to participants now, 22 under way, 3 of them phase 3. Pneumonia, Ventilator-Associated · France.

Enrollment
37th of 47
38 · median 161
Started
2018
with 1 other
Phase 3
16 of 80
3 open now
Registered
41st of 80
by date

Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, this one is the 37th largest by enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2018, is one of 16 in phase 3, and was the 41st registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

20 of the 80 studies in Pneumonia, Ventilator-Associated with a site in France are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Pneumonia, Ventilator-Associated with a site in France, or all of them as a file.
02

Study summary

The main objective of this study is to compare the median exposures at pharmacokinetic equilibrium of the two modalities of administration: 4-hours infusion of ceftolozane-tazobactam at a dosage of 2 gram three times a day vs 1-hour infusion of 2 gram three times a day.

Read the detailed description

Intensive care unit patients with ventilator associated-pneumonia often develop severe and rapidly life threatening Gram-negative Bacillus infections. Moreover, they present pathophysiological disturbances responsible for major pharmacokinetic changes (volume of distribution and glomerular filtration) which may lead to drugs under-exposure. Any delay in management or inadequate antibiotic therapy can have serious consequences in terms of prognosis. The association ceftolozane-tazobactam is an alternative to carbapenems in documented infections. Ceftolozane is a new cephalosporin, marketed, in combination with tazobactam (beta-lactamase inhibitor) under the name ZERBAXA®. ZERBAXA® is active on Gram-negative Bacillus, including Pseudomonas aeruginosa.

This is a prospective, randomized, open pharmacokinetic/pharmacodynamic study that compares two modalities of administration of a novel antibiotic, ZERBAXA® ceftolozane-tazobactam, by 4-hours infusion at the dosage of 2 gram three times a day vs. 1-hour infusion at the dosage of 2 g three times a day, among patients with ventilator associated-pneumonia to Pseudomonas aeruginosa.

The patient will be randomized either in the 4-hours or in the 1-hour infusion group. Follow up visits are daily for any intensive care patient. Those provided for biomedical research are carried out during the treatment period, at Day 15 and Day 28. For the pharmacokinetic study, 7 blood samples will be collected from 24 hours to 48 hours after the first ZERBAXA® administration.

03

Conditions studied

  • Ventilator-associated Pneumonia

Keywords

  • Pneumonia
  • Pseudomonas aeruginosa
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

inclusion criteria

  • patients with ventilator associated-pneumonia to Pseudomonas aeruginosa
  • patients hospitalized in intensive care units
  • Pseudomonas aeruginosa susceptible to ceftolozane-tazobactam
  • Simplified Acute Physiological Score II (SAPS II () > 20
  • Expected duration of survival > 7 days
  • of the patient or, failing that, the patient's close or trustworthy person
  • Affiliated to a social security scheme or equivalent

Non inclusion criteria:

  • history of allergy to one of the two molecules
  • history of allergy to betalactamines
  • Strain Isolated resistant to Ceftolozane-Tazobactam combination
  • Renal insufficiency with a evaluated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) \< 50 ml/min
  • Patient on dialysis or under continuous hemodiafiltration
  • pregnant or nursing women
  • patient benefiting from a system of legal protection for adults
  • patient with active immunodepression.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Active comparator
    1 hour infusion

    The first group corresponds to 1-hour infusion : First administration of ceftolozane-tazobactam with 2000 mg by infusion for 60 minutes every 8 hours. 24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48.

    Drug: 1 hour infusion

  • Experimental
    4 hours infusion

    The second group corresponds to 4-hours infusion: First administration of ceftolozane-tazobactam with 2000 mg by infusion for 4 hours every 8 hours. 24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48. .

    Drug: 4 hours infusion

Interventions

  • Drug1 hour infusion

    Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 60 minutes every 8 hours.

    Also known as: Zerbaxa 1 g/0.5 g powder

  • Drug4 hours infusion

    Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 4 hours every 8 hours

    Also known as: Zerbaxa 1 g/0.5 g powder

06

What researchers measure

Primary outcomes

  1. Time that the concentration spends above 5 Minimum inhibitory Concentration (T>5*MIC)

    The primary endpoint is the time that the concentration spends above 5\* Minimum inhibitory Concentration, expressed as a percentage of the time interval between two administrations. The T\>5\* Minimum inhibitory Concentration will be determined for each patient from the concentration profile measured over an 8-hour post-administration interval. Since protein binding is low (\<20%), the total concentration (sum of free form and plasma protein bound) will be used as a marker for free concentration. Therefore, the T\>5\* Minimum inhibitory Concentration will be calculated from the total concentrations. Our study will focus on only Pseudomonas aeruginosa Pneumonia acquired under mechanical ventilation with a critical Minimum inhibitory Concentration of 4 mg/l, T\>5\* Minimum inhibitory Concentration will then correspond to a residual serum concentration of 20 mg/l.

    Time frame: Time between two administrations (8 hours)

Secondary outcomes

  1. Percentage of patients with concentrations greater than 5*Minimum inhibitory Concentration

    The percentage of patients with concentrations greater than 5\*Minimum inhibitory Concentration over an 8-hour post administration interval.

    Time frame: Time between two administrations (8 hours)

  2. Bactericidal rate

    Bactericidal rate obtained in vitro using the Hollow Fiber device. This rate is determined for broncho-alveolar concentrations estimated in patients with pneumonia acquired during ventilation

    Time frame: at Day 10

  3. Percentage of patients recovering at the end of the treatment period

    Number of patients recovering in relation to the total number of patients

    Time frame: at Day 10

  4. Percentage of patients failing at the end of the treatment period

    Number of patients failing in relation to the total number of patients

    Time frame: at Day 10

  5. Number of days without artificial ventilation

    The number of days without artificial ventilation

    Time frame: at Day 28

  6. The duration of hospitalization

    the duration of hospitalization in number of day

    Time frame: at Day 28

  7. Survival at D28

    survival in number of patient alive

    Time frame: at Day 28

  8. The alveolar concentration of Ceftolozane-Tazobactam

    The alveolar concentration of Ceftolozane-Tazobactam from a sample of the alveolar fluid produced by bronchial fibroscopy between the 24th hour and the 48th hour

    Time frame: between 24 hour and 48 hour after time 0

  9. Evaluation of the serious adverse events

    Evaluation of the serious adverse events at the doses and regimen recommended in the trial

    Time frame: Day 28

07

Study locations

1 site
  • Service Réanimation Polyvalente - CHU Rangueil
    Toulouse, 31059, France
08

References and documents

Publications

  • Colomb-Cotinat M, Lacoste J, Brun-Buisson C, Jarlier V, Coignard B, Vaux S. Estimating the morbidity and mortality associated with infections due to multidrug-resistant bacteria (MDRB), France, 2012. Antimicrob Resist Infect Control. 2016 Dec 12;5:56. doi: 10.1186/s13756-016-0154-z. eCollection 2016. PubMed 27999665 ↗
  • Vincent JL, Bassetti M, Francois B, Karam G, Chastre J, Torres A, Roberts JA, Taccone FS, Rello J, Calandra T, De Backer D, Welte T, Antonelli M. Advances in antibiotic therapy in the critically ill. Crit Care. 2016 May 17;20(1):133. doi: 10.1186/s13054-016-1285-6. PubMed 27184564 ↗
  • Gelfand MS, Cleveland KO. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015 Sep 1;61(5):853-5. doi: 10.1093/cid/civ411. Epub 2015 May 28. No abstract available. PubMed 26021991 ↗
  • Monogue ML, Pettit RS, Muhlebach M, Cies JJ, Nicolau DP, Kuti JL. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6578-6584. doi: 10.1128/AAC.01566-16. Print 2016 Nov. PubMed 27550351 ↗
  • Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016 Jan;56(1):56-66. doi: 10.1002/jcph.566. Epub 2015 Aug 25. PubMed 26096377 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Feb 2025, 76 months.

Of 16 phase 3 interventional studies under Pneumonia, Ventilator-Associated, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 59. This study's 76 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2018
First posted
Jul 10, 2018
StartActual
Sep 20, 2018
Primary completionActual
Feb 2, 2025
CompletionActual
Feb 2, 2025
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 9, 2026
Enrollment
80 (estimated)→38 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Completed
    Enrollment 80 (estimated)→38 (actual)
    + 6 other changes: identifiers, verification date, date precision, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03581370
Responsible party
Sponsor
First posted
Jul 10, 2018
Start date
Sep 20, 2018
Primary completion
Feb 2, 2025
Completion
Feb 2, 2025
Last update
Nov 9, 2026

Study contacts

Stéphanie RUIZ, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion